Список проголосовавших за комментарий "Новости по теме:<br/> VVUS upgraded to Hold from Underperform at Jefferies<br/> <br/> VIVUS price target raised to $52 from $39 at Rodman & Renshaw.<br/> VIVUS approval a positive for Orexigen, says Leerink — Leerink believes approval of VIVUS's (VVUS) Qsymia is a positive for Orexigen (OREX) as it demonstrates the FDA's commitment to approving obesity drugs. The firm raised its price target for Orexigen to $12 from $10 and keeps an Outperform rating on the stock. Leerink expects near-term trading volatility in Arena Pharmaceuticals (ARNA) and VIVUS and recommends focusing on upside with Orexigen. <br/> Обе акции (+ARNA) имеют большой потенциал роста. Волатильность высока."